The principal objectives of the SPORE Lung Cancer Screening and Tissue Procurement CORE are to: (1) screen high risk smoker and ex-smoker patients identified through community and institutionally-based pulmonologists with sputum cytology to identify subjects with moderate or severe dysplasia; (2) obtain, classify, and bank sputum samples from the above; (3) support SPORE clinical investigations by obtaining bronchoscopy, serum, and urine specimens as required; and (4) maintain a registry of demographic data on all above patients. The CORE will create an archive of specimens, clinical, and demographic data for use in longitudinal investigations to evaluate hypotheses concerning the biological basis of lung carcinogenesis. The high risk population will be patients with airflow obstruction who have smoking histories of 40 or more pack years. This patient group has been selected because the risk for lung cancer has been found to increase in proportion to degree of airflow obstruction within smoking populations. The total accrual goal for the three year SPORE grant is 4,000 subjects. From prior experience, it is estimated that about 20% of these will have moderate or severe dysplasia. To enroll and instruct subjects on the selected method for sputum collection (i.e., early morning, spontaneous cough technique), the Lung Cancer Institute of Colorado's consortium of community and institutionally- based pulmonologists will be employed. Sputa collected from subjects will be processed and examined at the cytology laboratories of the following institutions: University of Colorado Health Sciences Center, Denver Veterans Administration Medical Center, Presbyterian Denver Hospital, and St. Mary's Medical Center, Grand Junction. Cytologic examinations will be performed by the SPORE pathologist panel to identify dysplastic patients for subsequent participation (if consent is obtained) in SPORE clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-02
Application #
3774013
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Ren, Shengxiang; Zhang, Shucai; Jiang, Tao et al. (2018) Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology 7:e1384108
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308
Ghosh, Moumita; Miller, York E; Vandivier, R William et al. (2018) Reply to Sohal: Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:1645-1646

Showing the most recent 10 out of 435 publications